Nasdaq Delisting Notice Hits BioRestorative Therapies Over Late 10-Q
BRTX sits 40% above its 52-week low of $0.159.
Summary
BioRestorative Therapies received a Nasdaq delisting notice for failing to file its Q2 2026 10-Q on time. The company has until October 20, 2026 to submit a compliance plan, with a possible extension to February 16, 2027.
Key Events · Legal and Risk Events · BRTX
-
Nasdaq Delinquency Notice Received
On August 21, 2026, Nasdaq notified the company it is not in compliance with Listing Rule 5250(c)(1) for failing to timely file its Form 10-Q for the quarter ended June 30, 2026.
-
Compliance Plan Deadline
The company has until October 20, 2026 to submit a plan to regain compliance. If accepted, Nasdaq may grant an exception up to 180 days from the 10-Q due date, or until February 16, 2027.
-
No Immediate Trading Halt
The notice has no immediate effect on listing; BRTX continues to trade on The Nasdaq Capital Market while the company works to file the 10-Q and submit a compliance plan.
-
Compounding Distress Signals
This delisting notice follows a going-concern warning, a suspension of all product shipments on August 14, 2026, and the July 2026 resignations of the CEO and CFO claiming a change in control.
Analysis · BRTX · Industrial Applications And Services
A Nasdaq delinquency notice landed on BioRestorative Therapies on August 21, 2026, after the company failed to file its Q2 2026 Form 10-Q on time. Trading continues for now, but the company must submit a compliance plan by October 20, 2026. If Nasdaq rejects the plan, an appeal is possible, yet delisting risk is now concrete. This compounds an already dire situation: a going-concern warning, a suspension of all product shipments on August 14, and the July resignations of the CEO and CFO citing a change in control. The late 10-Q points to deeper financial or operational disarray, and losing the Nasdaq listing would further impair liquidity and access to capital for a company with a market cap under $6 million.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 43.9% of the 999 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BRTX was trading at $0.22 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $0.16 to $1.89. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.